Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Initial treatment with a gonadotropin‐releasing hormone (GnRH) agonist increases fat mass, decreases lean body mass, and decreases bone mineral density (BMD) in men with prostate carcinoma. To the authors' knowledge, little is known regarding either the long‐term effects of treatment or predictors of treatment‐related changes in BMD and body composition. METHODS: The authors analyzed prospective 12‐month data from 65 men during initial and long‐term GnRH agonist treatment for prostate carcinoma. Relationships between baseline characteristics (age, treatment duration, body mass index, and baseline values for outcome of interest) and changes in lean mass, fat mass, and BMD were assessed using univariate and multivariate regression models. RESULTS: Mean BMD of total hip decreased by 1.9 ± 2.7%, lean body mass decreased by 2.0 ± 3.3%, and fat mass increased by 6.6 ± 9.4% at 12 months (P < 0.001 for each comparison). Twenty‐three men (35%) had received treatment with a GnRH agonist before study entry, and the mean (± standard deviation) duration of previous treatment was 35 ± 41 months. Longer duration of previous GnRH agonist treatment was found to independently predict less fat accumulation and less loss of lean body mass in multivariate models. In contrast, the duration of GnRH agonist treatment did not significantly predict changes in BMD. Other covariates did not appear to predict changes in body composition or BMD consistently. CONCLUSIONS: The results of the current study showed that fat mass increased and lean body mass decreased mostly during initial GnRH agonist therapy whereas BMD decreased steadily during initial and long‐term treatment. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“to the regulation of both bone formation and bone resorption in men.(21,22) Serum estradiol levels are”
BackgroundChanges in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 2×
“GnRH agonists also increase fat mass and decrease lean body mass.(6,7) These treatment-related changes in body composition may contribute to fatigue, emotional distress, and decreased quality of life.”
BackgroundMethodSelf-citationSlemenda, C. W., Longcope, C., Zhou, L., Hui, S. L., Peacock, M., & Johnston, C. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119701 · Cited by 455
Khosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283 · cited 1×
“to the regulation of both bone formation and bone resorption in men.(21,22) Serum estradiol levels are”
BackgroundSelf-citationHERR, H. W., & O’SULLIVAN, M. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67533-7 · Cited by 250
Smith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188 · cited 1×
“MATERIALS AND METHODS Subjects and Study Design These analyses included subjects from the control groups from three randomized, controlled trials for treatment-related bone loss in men with nonmetastatic prostate carcinoma.(2,11,12) All subjects in the analyses were either receiving treatment with a GnRH agonist for p…”
MethodSelf-citationThe effects of menopause on longitudinal bone loss from the spine
Pouilles, J. M., Tremollieres, F., & Ribot, C. (1993) · Calcified Tissue International · doi:10.1007/bf00310195 · Cited by 149 · cited 1×
“In late menopause, BMD decreases more slowly.(13,14) In large prospective studies of postmenopausal women with os-”
Background
Cited by
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Self-citationAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M.-H., & Carroll, P. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm168 · Cited by 520
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Self-citationMetabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Self-citationMichaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330
Self-citationResistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
GALVÃO, D. A., NOSAKA, K., TAAFFE, D. R., SPRY, N., KRISTJANSON, L. J., MCGUIGAN, M. R., SUZUKI, K., YAMAYA, K., & NEWTON, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Endocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.021 · Cited by 200
Self-citationGalvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., Turner, D., & Newton, R. U. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.51 · Cited by 198
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
Self-citationStorer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Metadata
- Authors
- Lee, H., McGovern, K., Finkelstein, J. S., & Smith, M. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-10-03
- Volume
- 104
- Issue
- 8
- Pages
- 1633-1637
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2019530713
- Cited by
- 148
- References
- 9
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.